DK0804161T3 - Kontinuerlig fremgangsmåde til formaling af farmaceutiske materiealer - Google Patents

Kontinuerlig fremgangsmåde til formaling af farmaceutiske materiealer

Info

Publication number
DK0804161T3
DK0804161T3 DK95919062T DK95919062T DK0804161T3 DK 0804161 T3 DK0804161 T3 DK 0804161T3 DK 95919062 T DK95919062 T DK 95919062T DK 95919062 T DK95919062 T DK 95919062T DK 0804161 T3 DK0804161 T3 DK 0804161T3
Authority
DK
Denmark
Prior art keywords
agent
grinding media
milling chamber
particle size
less
Prior art date
Application number
DK95919062T
Other languages
English (en)
Inventor
David A Czekai
Larry P Seaman
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Application granted granted Critical
Publication of DK0804161T3 publication Critical patent/DK0804161T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/888—Shaping or removal of materials, e.g. etching
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/90—Manufacture, treatment, or detection of nanostructure having step or means utilizing mechanical or thermal property, e.g. pressure, heat
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Crushing And Pulverization Processes (AREA)
  • Disintegrating Or Milling (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95919062T 1994-05-25 1995-05-08 Kontinuerlig fremgangsmåde til formaling af farmaceutiske materiealer DK0804161T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/249,787 US5718388A (en) 1994-05-25 1994-05-25 Continuous method of grinding pharmaceutical substances
PCT/US1995/005728 WO1995031973A1 (en) 1994-05-25 1995-05-08 Continuous method of grinding pharmaceutical substances

Publications (1)

Publication Number Publication Date
DK0804161T3 true DK0804161T3 (da) 2002-03-04

Family

ID=22944996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95919062T DK0804161T3 (da) 1994-05-25 1995-05-08 Kontinuerlig fremgangsmåde til formaling af farmaceutiske materiealer

Country Status (14)

Country Link
US (1) US5718388A (da)
EP (1) EP0804161B1 (da)
JP (1) JP3607294B2 (da)
AT (1) ATE208191T1 (da)
AU (1) AU2476195A (da)
CA (1) CA2190134C (da)
DE (1) DE69523781T2 (da)
DK (1) DK0804161T3 (da)
ES (1) ES2165913T3 (da)
IL (1) IL113851A (da)
MY (1) MY113569A (da)
PT (1) PT804161E (da)
TW (1) TW460297B (da)
WO (1) WO1995031973A1 (da)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US6832735B2 (en) * 2002-01-03 2004-12-21 Nanoproducts Corporation Post-processed nanoscale powders and method for such post-processing
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6000646A (en) * 1998-03-16 1999-12-14 Ranne; Bethyl H. Double barrel media mill for grinding and dispersing particulate matter and pigment for paint, coatings, ink and other fluid pigment vehicles
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
EP1185371B2 (en) 1999-06-01 2008-11-12 Elan Pharma International Limited Small-scale mill and method thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US20040026546A1 (en) 2000-04-26 2004-02-12 Czekai David A Apparatus for sanitary wet milling
ATE389455T1 (de) 2000-05-10 2008-04-15 Jagotec Ag Zerkleinerung mittels mahlkörper
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ES2274013T3 (es) * 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
DE60123844T2 (de) * 2001-04-27 2007-08-30 Kansai Paint Co., Ltd., Amagasaki Verfahren und vorrichtung zum dispergieren von farbstoffen in einem flüssigen medium
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
DE60203506T2 (de) * 2001-06-22 2006-02-16 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US8403367B2 (en) 2001-08-02 2013-03-26 Eastman Kodak Company Authentication using near-field optical imaging
US6722699B2 (en) 2001-08-02 2004-04-20 Eastman Kodak Company Authentication using near-field optical imaging
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003024425A1 (en) * 2001-09-19 2003-03-27 Elan Pharma International, Ltd. Nanoparticulate insulin formulations
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
CA2463495C (en) * 2001-10-12 2011-05-24 Baudax Bio, Inc. Compositions having a combination of immediate release and controlled release characteristics
EP1450863A4 (en) * 2001-11-07 2009-01-07 Imcor Pharmaceutical Company PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS
MXPA04006017A (es) 2001-12-20 2005-06-08 Femmepharma Inc Suministro de farmacos por via vaginal.
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
US6699963B2 (en) 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003222027A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
EP2263650A3 (en) 2002-04-12 2013-12-25 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7763278B2 (en) * 2002-06-10 2010-07-27 Elan Pharma International Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
CA2498207C (en) * 2002-09-11 2012-03-13 Elan Pharma International Ltd. Gel-stabilized nanoparticulate active agent compositions
AU2003273757A1 (en) * 2002-10-09 2004-05-04 Novozymes A/S A method for improving particle compositions
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
ES2365012T3 (es) * 2002-11-12 2011-09-20 Elan Pharma International Limited Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1578421A4 (en) 2003-01-02 2009-04-22 Femmepharma Holding Co Inc PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
WO2004078162A1 (en) * 2003-01-31 2004-09-16 Elan Pharma International Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US20070056465A1 (en) * 2003-03-06 2007-03-15 Rensselaer Polytechnic Institute Rapid generation of nanoparticles from bulk solids at room temperature
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081003A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
EP1626742A1 (en) * 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilization of dispersions of nanoparticulate active agents with gamma radiation
ATE415946T1 (de) * 2003-08-08 2008-12-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
US7618181B2 (en) * 2003-10-23 2009-11-17 Kansai Paint Co., Ltd. Method for dispersing pigment in liquid medium
US7879360B2 (en) * 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP1621200A1 (en) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate
KR20130030305A (ko) 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
EA013741B1 (ru) * 2004-12-15 2010-06-30 Элан Фарма Интернэшнл Лтд. Дисперсии наночастиц такролимуса с повышенными растворимостью в воде и биодоступностью, способы их приготовления и применения
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
EA011594B1 (ru) * 2004-12-30 2009-04-28 Синвеншен Аг Композиция, включающая агент, обеспечивающий сигнал, имплантируемый материал и лекарство
CN104083342A (zh) * 2004-12-31 2014-10-08 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
EP1835890A2 (en) * 2005-01-06 2007-09-26 Elan Pharma International Limited Nanoparticulate candesartan formulations
BRPI0519754A2 (pt) * 2005-01-13 2009-03-10 Cinv Ag materiais compàsitos contendo nanopartÍculas de carbono
CA2591944A1 (en) * 2005-01-24 2006-07-27 Cinvention Ag Metal containing composite materials
CA2597716A1 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
EA200701997A1 (ru) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиция из наночастиц бисфосфоната
WO2006097503A2 (en) * 2005-03-18 2006-09-21 Cinvention Ag Process for the preparation of porous sintered metal materials
KR20070121786A (ko) * 2005-03-23 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 코르티코스테로이드 및 항히스타민 제제
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
CA2603084A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
WO2006110811A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
EP1888037A2 (en) * 2005-05-10 2008-02-20 Elan Pharma International Limited Nanoparticulate clopidogrel formulations
WO2008010784A1 (en) * 2005-05-16 2008-01-24 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising a cephalosporin
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AU2006309295B2 (en) * 2005-06-03 2012-04-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
US20060275372A1 (en) 2005-06-03 2006-12-07 Elan Pharma International Limited Nanoparticulate imatinib mesylate formulations
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
WO2006135689A2 (en) * 2005-06-09 2006-12-21 Elan Pharma International, Limited Nanoparticulate ebastine formulations
BRPI0611626A2 (pt) * 2005-06-13 2010-09-21 Elan Pharma Int Ltd formulações da combinação de nanopartìculas de clopidogrel e aspirina
WO2006138421A2 (en) * 2005-06-15 2006-12-28 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
JP2009500054A (ja) * 2005-07-01 2009-01-08 シンベンション アーゲー 網状複合材料を含む医療装置
KR20080033335A (ko) * 2005-07-01 2008-04-16 신벤션 아게 다공성 망상 복합 물질의 제조 방법
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
GB0516549D0 (en) * 2005-08-12 2005-09-21 Sulaiman Brian Milling system
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
BRPI0617450A2 (pt) * 2005-10-18 2011-07-26 Cinv Ag partÍculas de termocura e mÉtodos para produÇço das mesmas
MX336930B (es) 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
ES2684821T3 (es) 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Derivados de aminoácidos multicíclicos y métodos de su uso
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US20070264349A1 (en) * 2006-03-07 2007-11-15 Novavax, Inc. Nano-structured compositions and methods of making and using the same
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
BRPI0712130A2 (pt) 2006-05-30 2012-01-17 Elan Pharma Int Ltd formulações de posaconazol em nanopartìculas
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
EP2049084A2 (en) * 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
MX2009000391A (es) * 2006-07-12 2009-06-30 Elan Pharma Int Ltd Formulación de modafinilo en forma de nano-partículas.
BRPI0717721A2 (pt) 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2008087214A1 (en) * 2007-01-19 2008-07-24 Cinvention Ag Porous, non-degradable implant made by powder molding
CN101646764A (zh) * 2007-02-28 2010-02-10 金文申有限公司 高表面积培养系统
EP2129768A2 (en) * 2007-02-28 2009-12-09 Cinvention Ag High surface cultivation system with surface increasing substrate
CA2677722A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system with filler
WO2008104599A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system bag
CA2715422A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
WO2010096558A1 (en) 2009-02-18 2010-08-26 Eyeon Particle Sciences Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
PL2952191T3 (pl) 2009-06-12 2019-02-28 Sunovion Pharmaceuticals Inc. Apomorfina w postaci do podawania podjęzykowego
HUP0900384A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
HUP0900376A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
CN102497857A (zh) 2009-06-19 2012-06-13 纳米模型匈牙利有限公司 纳米结构的西地那非碱、其药学可接受的盐和共结晶、它们的组合物、其制备方法和包含它们的药物组合物
US20120135053A1 (en) 2009-06-19 2012-05-31 Filipcsei Genoveva Nanoparticulate telmisartan compositions and process for the preparation thereof
CN102711749A (zh) 2009-11-05 2012-10-03 莱西肯医药有限公司 用于癌症治疗的色氨酸羟化酶抑制剂
CN102753168A (zh) 2010-02-10 2012-10-24 莱西肯医药有限公司 用于治疗转移性骨病的色氨酸羟化酶抑制剂
EP2560624B1 (en) 2010-04-23 2018-07-04 KemPharm, Inc. Therapeutic formulation for reduced drug side effects
US9511037B2 (en) 2010-04-23 2016-12-06 Genco Sciences Llc Compositions for reduction of side effects
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
HUP1000327A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation
HUP1000325A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
AU2011305567A1 (en) 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
DE102010052656B4 (de) * 2010-11-26 2025-08-21 Netzsch-Feinmahltechnik Gmbh Hydraulische mahlkugelzu- und abfuhr für rührwerkskugelmühlen
DK2651357T3 (da) 2010-12-16 2020-06-02 Sunovion Pharmaceuticals Inc Sublinguale film
WO2013074988A1 (en) 2011-11-17 2013-05-23 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
RU2697862C2 (ru) * 2012-02-28 2019-08-21 Айсьютика Холдингз Инк. Ингаляционные фармацевтические композиции
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
WO2013166385A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP3808339B1 (en) 2012-05-03 2025-11-12 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN105121023B (zh) * 2013-02-28 2017-08-25 太阳化学公司 用于在液体分散液中制造研磨的固体的装置和连续方法
BR112015032262A2 (pt) 2013-06-28 2017-07-25 Rexahn Pharmaceuticals Inc composições de nanopartículas e formulações de compostos de piperazina
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
US20150343453A1 (en) * 2014-05-28 2015-12-03 NanoCentrix L.L.C. Fluid energy media mill system and method
CN106794251B (zh) 2014-08-18 2020-12-29 阿尔科姆斯制药爱尔兰有限公司 阿立哌唑前体药物组合物
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
EP3285771B1 (en) 2015-04-21 2025-02-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
CA2984421C (en) 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN108135838A (zh) 2015-10-16 2018-06-08 马瑞纳斯制药公司 包含纳米粒的可注射神经类固醇制剂
WO2017143017A1 (en) 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2018052053A1 (ja) 2016-09-13 2018-03-22 協和発酵キリン株式会社 医薬組成物
CN111971284A (zh) 2017-12-27 2020-11-20 埃默里大学 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式
EP3840754A4 (en) 2018-08-23 2022-09-14 Sunovion Pharmaceuticals Inc. ACID ADDITIONAL SALTS OF APOMORPHINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE THEREOF
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
WO2021072325A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
JP7780431B2 (ja) 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
EP3928772B1 (en) 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanoparticulate composition
JP2022052396A (ja) * 2020-09-23 2022-04-04 株式会社リコー 分散液の製造方法及び製造装置
CN112427096B (zh) * 2020-10-19 2022-01-28 上海旭军机械有限公司 一种纳米材料的研磨设备
CN116408192B (zh) * 2021-12-29 2026-02-17 南方科技大学 一种表界面调控法制备微纳米碳颗粒的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2595117A (en) * 1950-03-08 1952-04-29 Smidth & Co As F L Method and apparatus for grinding
ES293103A1 (es) * 1962-11-12 1964-03-16 Aziende Colori Naz Affini Acna S P A Procedimiento para la preparación de quinacridona en forma de pigmento
US3713593A (en) * 1970-08-11 1973-01-30 Freeport Sulphur Co Fine media milling process
SU514627A1 (ru) * 1972-07-19 1976-05-25 Институт Биохимии И Физиологии Микроорганизмов Ан Ссср Дезинтегратор дл микроорганизмов
US4860957A (en) * 1988-03-29 1989-08-29 Lidstroem Lars Treatment of middlings
JPH02132162A (ja) * 1988-11-11 1990-05-21 Showa Shell Sekiyu Kk 微小ジルコニア焼成ボールによる顔料の分散方法
US5174512A (en) * 1988-12-16 1992-12-29 Snamprogetti S.P.A. Grinding process and a continuous high-capacity micronizing mill for its implementation
JPH02196719A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
JPH04166246A (ja) * 1990-10-31 1992-06-12 Matsushita Electric Ind Co Ltd 媒体撹拌ミル及び粉砕方法
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
JPH05253509A (ja) * 1991-05-08 1993-10-05 Fuaimatetsuku:Kk 流通式媒体攪拌超微粉砕機
JPH05253512A (ja) * 1992-03-11 1993-10-05 Chuo Kakoki Kk 粉粒体又はスラリーの処理用媒体
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances

Also Published As

Publication number Publication date
JP3607294B2 (ja) 2005-01-05
EP0804161A1 (en) 1997-11-05
JPH10500593A (ja) 1998-01-20
EP0804161B1 (en) 2001-11-07
DE69523781T2 (de) 2002-06-13
DE69523781D1 (de) 2001-12-13
CA2190134A1 (en) 1995-11-30
ATE208191T1 (de) 2001-11-15
WO1995031973A1 (en) 1995-11-30
PT804161E (pt) 2002-04-29
CA2190134C (en) 2005-03-08
ES2165913T3 (es) 2002-04-01
IL113851A0 (en) 1995-08-31
MY113569A (en) 2002-04-30
IL113851A (en) 1999-12-22
TW460297B (en) 2001-10-21
US5718388A (en) 1998-02-17
AU2476195A (en) 1995-12-18

Similar Documents

Publication Publication Date Title
DK0804161T3 (da) Kontinuerlig fremgangsmåde til formaling af farmaceutiske materiealer
DK0760653T3 (da) Fremgangsmåde til formaling af farmaceutiske stoffer
ATE188391T1 (de) Methode und vorrichtung zur flüssigkeitschromatographie
WO1997021490A3 (en) Process for separation and recovery of waste carpet components
WO2002045691A3 (en) Laboratory scale milling process
PL323444A1 (en) Method of and apparatus for elestrostatically charging particles suspended in fluid gaseous medium and separating them therefrom
CA2237019A1 (en) System for filtering medical and biological fluids
CA2056422A1 (en) Electrostatic separator
AU1784195A (en) Drying suspensions of materials
KR101982529B1 (ko) 토양주입용 액상활성탄 제조방법
GB9026028D0 (en) A screening system
EP0244999A3 (en) Use of charged particles in the membrane filtration of liquid cell culture media
US3521428A (en) Phase separation
BR8803484A (pt) Processo para producao de particulas solidas de tamanho medio de particula reduzido
EP1004526A3 (de) Vorrichtung zum Abscheiden von Feststoffen aus einem Luftstrom
KR960700819A (ko) 지르코늄 실리케이트 연마 매체 및 분쇄 방법(zirconium silicate grinding medium and method of milling)
EP0086642A3 (en) Filtration method and apparatus
JPS59154149A (ja) 固体粒子の粉砕法
HUT60643A (en) Method for filtering the dust content of air and air-filtering insert
CA2262746A1 (en) Method of and apparatus for separating solvent in a feed of solvent and deasphalted oil
JPH10309454A (ja) 湿式媒体分散装置